The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 102-104

  Hurdle, Julian G ^a   O'Neill, Alex J ^a   Chopra, Ian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

GISA; Mupirocin resistant Staphylococcus aureus

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; GLYCOPEPTIDE; ISOLEUCINE TRANSFER RNA; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CARRIER; BACTERIUM MUTANT; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GROWTH RATE; MIXED CELL CULTURE; NONHUMAN; NOSE CAVITY; POINT MUTATION; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; ISOLEUCINE-TRNA LIGASE; MUPIROCIN; POINT MUTATION; STAPHYLOCOCCUS AUREUS;

EID: 0346025674     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh020     Document Type: Article

References (10)

1. Hudson, I. R. B. (1994). The efficacy of intranasal mupirocin in the prevention of staphylococcal infections -a review of recent experience. Journal of Hospital Infection 27, 81-98.
2. Cookson, B. D. (1998). The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. Journal of Antimicrobial Chemotherapy 41, 11-8.
3. Decousser, J. W., Pina, P., Ghnassia, J. C. et al. (2003). First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. European Journal of Clinical Microbiology and Infectious Diseases 22, 318-9.
4. Antonio, M., McFerran, N. & Pallen, M. J. (2002). Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 46, 438-42.
5. Andersson, D. I. & Levin, B. R. (1999). The biological cost of antibiotic resistance. Current Opinion in Microbiology 2, 489-93.
6. Harbarth, S., Liassine, N., Dharan, S. et al. (2000). Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 31, 1380-5.
7. Watanabe, H., Masaki, H., Asoh, N. et al. (2001). Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 39, 3775-7.
8. O'Neill, A. J., Cove, J. H. & Chopra, I. (2001). Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 47, 647-50.
9. Lenski, R. E. (1988). Experimental studies of pleiotropy and epistasis in Escherichia coli. I. Variation in competitive fitness among mutants resistant to virus T4. Evolution 42, 425-32.
10. Baquero, F. (2001). Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resistance Updates 4, 93-105.